Renal cell carcinoma
Adjuvant therapy in RCC
Obiettivo della formazione: To assess the recurrence risk after nephrectomy and appropriately select patients who are at high risk of renal cell carcinoma (RCC) recurrence and may benefit from adjuvant treatment.
Specializzazione: Urology, Medical oncology, Clinical oncology
Pubblico target: Specialists (CME: basic, intermediate), Residents (senior)
Aggiornamento più recente: January 2025
Premessa:
Regulatory approval status of drugs mentioned in this CME course, restricted to the adjuvant treatment setting (status 22 January 2025)
This educational platform includes case challenges with treatment options that may not be indicated for this use in your country. Please refer to your local prescribing information.